Labrycor

Isoprenaline Hydrochloride, the active ingredient in Labrycor, is a beta‑adrenergic agonist presented as an injectable solution for intravenous use. It is employed to increase heart rate, improve myocardial contractility, and provide bronchodilation in acute clinical settings.\nGNH India supplies Labrycor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isoprenaline Hydrochloride acts on the cardiovascular and respiratory systems to manage acute rhythm and airway conditions.\n\nBradycardia: raises heart rate to correct symptomatic slow rhythm.\nHeart block: improves conduction to alleviate block-related bradyarrhythmias.\nAsthma (bronchospasm): relaxes airway smooth muscle to relieve acute bronchoconstriction.\nHypotension: increases cardiac output and vascular tone to support blood pressure.

Adverse reactions may occur with intravenous administration of Isoprenaline Hydrochloride.\n\nCommon Side Effects:\n- Tachycardia: excessive increase in heart rate.\n- Palpitations: awareness of rapid heartbeat.\n- Tremor: fine muscle shaking.\n- Headache: mild to moderate pain.\n\nSerious or Rare Side Effects:\n- Arrhythmias: potentially life‑threatening rhythm disturbances.\n- Myocardial ischemia: reduced blood flow to heart muscle.\n- Severe hypotension: abrupt drop in blood pressure.\n- Allergic reactions: rash, itching, or anaphylaxis.

Careful monitoring is required when using Isoprenaline Hydrochloride intravenously.\n\nCardiac monitoring: observe heart rate and rhythm throughout infusion.\nBlood pressure monitoring: watch for hypertension or hypotension.\nAsthma caution: monitor for paradoxical bronchospasm.\nRecent myocardial infarction: avoid due to risk of ischemia.\nStore at ambient temperature: keep in original container, protect from light and moisture.

Isoprenaline Hydrochloride can interact with several cardiovascular agents.\n\nMajor Interactions (Avoid):\n- Beta‑blockers: antagonize therapeutic effect and may cause severe bradycardia.\n- Calcium channel blockers: additive cardiac effects increase arrhythmia risk.\n- MAO inhibitors: potentiate cardiovascular stimulation.\n\nModerate Interactions (Monitor Closely):\n- Diuretics: may enhance hypotensive response.\n- Digitalis glycosides: increased risk of arrhythmias.